Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer

靶向宫颈癌中 HPV E6 依赖性缺氧诱导的 NF-κ B

基本信息

项目摘要

DESCRIPTION (provided by applicant): PROJECT ABSTRACT Cervical cancer is the leading cause of cancer-specific mortality amongst women worldwide and the human papilloma virus (HPV) plays a pathophysiologic role in cervical carcinogenesis in over 95% of cases. For over half a century, it has become increasingly established that intratumoral hypoxia is associated with an aggressive clinical phenotype, manifested by resistance to radiation and chemotherapy, a high risk of recurrence and metastasis, and shortened overall survival. The mechanistic underpinnings that account for these adverse clinical sequelae of hypoxia have not been elucidated. We recently identified a biochemical link between HPV infection and hypoxia in cervical cancer (Cancer Cell, 14:394, 2008). Specifically, we found that the HPV-encoded E6 protein mediates prolonged activation of the NF kappa B (NF-:B) signaling pathway under hypoxic conditions. As oxygen becomes a limiting substrate, E6 effectively targets CYLD, a negative regulator of the NF-:B pathway, for proteasome-mediated degradation, and thereby allows for unrestricted NF-:B activation. Through its transcriptional activity, NF-:B drives proliferation, survival, neo-angiogenesis, invasion and metastasis. Thus, we postulate that the poor clinical outcomes associated with hypoxia can in large part be attributed to E6-mediated, hypoxia-induced NF- :B activation. In pursuit of our hypothesis, we propose three aims in which we will be: 1) elucidating some of the key remaining biochemical and molecular cues that drive the E6-CYLD interaction (Specific Aim 1), 2) examining the relative effects of hypoxia-induced versus constitutive NF-:B activation on cervical tumorigenesis and metastasis development in murine xenografts models (Specific Aim 2), and 3) prospectively studying the relationship between hypoxia and NF-:B activation and CYLD expression in tumors of cervical cancer patients (Specific Aim 3). We have assembled a team of physician-scientists with diverse skill sets from various disciplines, including medical oncology, gynecologic oncology, and gynecologic pathology to further our molecular understanding of the hypoxic phenotype. Accomplishments from this proposal represent a necessary prelude to translate our work to early phase clinical trials aimed at targeting hypoxia-induced NF-:B activation, which can take advantage of the potentially high therapeutic index afforded by HPV positivity.
描述(由申请人提供): 项目摘要宫颈癌是全球女性癌症特异性死亡率的主要原因,而人类乳头状瘤病毒(HPV)在超过95%的病例中在宫颈癌中起病理生理作用。在半个多世纪的时间里,越来越多地确定肿瘤内缺氧与积极的临床表型有关,这表现为对放射和化学疗法的抗性,复发和转移的高风险,并缩短了总体生存。尚未阐明这些不良临床后遗症的机械基础尚未阐明。 我们最近确定了HPV感染与宫颈癌缺氧之间的生化联系(Cancer Cell,14:394,2008)。具体而言,我们发现HPV编码的E6蛋白在低氧条件下介导了NF Kappa B(NF-:B)信号通路的延长激活。随着氧成为有限的底物,E6有效地靶向CYLD,CYLD是NF-:B途径的负调节剂,用于蛋白酶体介导的降解,从而允许无限制的NF-:B激活。通过其转录活性,NF-:B驱动增殖,生存,新血管生成,入侵和转移。因此,我们假设与缺氧相关的较差的临床结果可能归因于E6介导的缺氧诱导的NF-:B激活。为了追求我们的假设,我们提出了三个目标:1)阐明剩余的某些生物化学和分子提示的关键,这些关键驱动E6-cyld相互作用(特定目的1),2)检查缺氧引起的低氧相对效果,构建量子和牛乳属性图2) 3)前瞻性研究宫颈癌患者肿瘤中缺氧与NF-激活与CYLD表达之间的关系(特定目标3)。我们已经组建了一支来自各种学科的医师科学家团队,包括医学肿瘤学,妇科肿瘤学和妇科病理学,以进一步了解我们对低氧表型的分子理解。该提案的成就是将我们的工作转化为旨在靶向缺氧引起的NF-:B激活的早期临床试验的必要前奏,该试验可以利用HPV阳性提供的潜在高治疗指数。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATTHEW B RETTIG其他文献

MATTHEW B RETTIG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATTHEW B RETTIG', 18)}}的其他基金

A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
一项检查点抑制剂治疗以错配修复缺陷或双等位基因 CDK12 失活为特征的进行性转移性去势抵抗性前列腺癌男性的 2 期研究
  • 批准号:
    10917011
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
一项检查点抑制剂治疗以错配修复缺陷或双等位基因 CDK12 失活为特征的进行性转移性去势抵抗性前列腺癌男性的 2 期研究
  • 批准号:
    10417047
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
肾细胞癌中不依赖 HIF-α 的药物靶点
  • 批准号:
    9487898
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
肾细胞癌中不依赖 HIF-α 的药物靶点
  • 批准号:
    8921769
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
  • 批准号:
    8551641
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
  • 批准号:
    9097575
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
  • 批准号:
    8699713
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
  • 批准号:
    8912402
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
雄激素受体 N 末端区域抑制剂的鉴定
  • 批准号:
    8373260
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
靶向宫颈癌中 HPV E6 依赖性缺氧诱导的 NF-κ B
  • 批准号:
    8413407
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

环境治理目标下的公司财务、会计和审计行为研究
  • 批准号:
    72332002
  • 批准年份:
    2023
  • 资助金额:
    165.00 万元
  • 项目类别:
    重点项目
信用信息共享机制对企业会计稳健性、风险行为决策以及失信后果的影响研究
  • 批准号:
    72302198
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
套期会计有效性的研究:实证检验及影响机制
  • 批准号:
    72302225
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
新证券法对证券审计市场格局和会计师事务所行为策略的影响研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
新证券法对证券审计市场格局和会计师事务所行为策略的影响研究
  • 批准号:
    72202176
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
靶向宫颈癌中 HPV E6 依赖性缺氧诱导的 NF-κ B
  • 批准号:
    8413407
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
The Role of FKBP10 in Recessive Osteogenesis Imperfecta
FKBP10 在隐性成骨不全症中的作用
  • 批准号:
    8253962
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
The Role of FKBP10 in Recessive Osteogenesis Imperfecta
FKBP10 在隐性成骨不全症中的作用
  • 批准号:
    8331763
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
The Role of FKBP10 in Recessive Osteogenesis Imperfecta
FKBP10 在隐性成骨不全症中的作用
  • 批准号:
    8513969
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Project 1. PROLY 3-HYDROXYLASE (P3H) COMPLEX AND MATRIX CELL SIGNALING DEFECTS IN
项目 1. PROLY 3-羟化酶 (P3H) 复合物和基质细胞信号传导缺陷
  • 批准号:
    8508691
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了